Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
(firmenpresse) - MONTREAL -- (Marketwired) -- 04/09/13 -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that it has completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a, the Company's flagship oncology drug candidate, was measured in the HMEC cell line. HMEC are normal (non-cancerous) human mammary epithelial cells isolated from reduction mammoplasty tissue. The HMEC cell line is the standard cell line used for investigating the molecular and biochemical basis for in vitro toxicity of various drug candidates. The data of the present HMEC studies indicated that concentrations of up to 24 micromolar of Adva-27a did not appreciably inhibit the normal growth process of these cells.
"These data indicate that Adva-27a will likely not be toxic or damaging to healthy tissue, a key component for our planned clinical trials, as toxicity is what stops most drugs in early development," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy."
Adva-27a is Sunshine Biopharma's lead anticancer compound which has proven very effective at killing multidrug resistant cancer cells in vitro. Current chemotherapy drugs are ineffective against multidrug resistant cancers. To date Adva-27a has been shown to effectively kill three different types of multidrug resistant cancer cell line including MES-SA/Dx5, a Uterine Sarcoma cell line, MCF-7/MDR, a breast cancer cell line and H69AR, a small-cell lung cancer cell line.
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a. In addition to the existing patents recently issued in the U.S. and Europe (pending elsewhere), Sunshine Biopharma's parent company, Advanomics Corporation, recently announced that it has filed a new patent application covering various composition matters and manufacturing processes of Adva-27a.
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 247148
Anzahl Zeichen: 0
contact information:
Town:
MONTREAL
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations"
steht unter der journalistisch-redaktionellen Verantwortung von
Sunshine Biopharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
